Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin® at ESGO 2026
- 9 of 10 patients at the highest dose remained free from peritoneal recurrence at 24 months at the recommended dose
Oslo, Norway, 17 February 2026 – Oncoinvent, a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin? after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026.
